Skip to main content
VCbacked
Log inGet Started

Lusaris Therapeutics

Boston, United States

Lusaris Therapeutics develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders.

$60.0M raised
Nov 2022
Series A
BiotechnologyNeuroscienceTherapeutics

Top Investors

RA Capital ManagementVenrock Healthcare Capital PartnersDeep Track CapitalBoxer Capital

Founder Contacts

30,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Lusaris Therapeutics

How much funding has Lusaris Therapeutics raised?
Lusaris Therapeutics has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in November 2022.
Who are Lusaris Therapeutics's investors?
Lusaris Therapeutics's investors include RA Capital Management, Venrock Healthcare Capital Partners, Deep Track Capital, Boxer Capital.
Where is Lusaris Therapeutics headquartered?
Lusaris Therapeutics is headquartered in Boston, United States.
What does Lusaris Therapeutics do?
Lusaris Therapeutics develops small-molecule neuroplastogen therapeutics for neuropsychiatric and neurological disorders.
What stage is Lusaris Therapeutics at?
Lusaris Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Lusaris Therapeutics — Funding & Investors." VCBacked, November 2, 2022, https://www.vcbacked.co/company/lusaris-therapeutics. Accessed July 3, 2026.
APA
VCBacked. (2022). Lusaris Therapeutics — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/lusaris-therapeutics
Wikipedia (cite web)
{{cite web |title=Lusaris Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lusaris-therapeutics |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Allterum Therapeutics
Houston$1.0M
AlpalifeBio
Woburn$9.8M
Renaissance BioScience
Vancouver$599K
Rapport Therapeutics
Boston$250.0M
Epsilogen
London$16.3M
Advanced Microbiome Interventions
Amsterdam$300K